Elicit: CD80/CD86 Blockade and T-Cell Dynamics

How does CD80/CD86 blockade by abatacept affect T-cell activation and tolerance?

Abstract

CD80/CD86 blockade by abatacept consistently reduces T-cell activation across multiple disease contexts through selective modulation of CD28-mediated costimulation. Treatment decreases expression of activation markers (CD38, ICOS, Ki-67) and reduces proliferation particularly in CD4+ T cells, with 7-10-fold fewer proliferating and activated effector memory CD4+ T cells observed in GVHD prevention. Abatacept shifts CD4+ compartments toward naive phenotypes while reducing central memory populations, with transcriptional analysis revealing decreased expression of genes regulating cell cycle and chromatin dynamics. CD8+ T-cell subsets remain relatively resistant to these effects, indicating lesser reliance on CD28 costimulation. The effects are reversible after treatment discontinuation, with T-cell populations returning to baseline within 6 months, indicating that abatacept maintains an altered immune state through continuous pharmacological inhibition rather than inducing permanent tolerance.

Effects on regulatory T cells are context-dependent and paradoxical: in rheumatoid arthritis, abatacept increases Treg numbers through reduced apoptosis but diminishes their suppressive function because CD80/CD86 blockade on responder T cells reduces susceptibility to Treg-mediated suppression, while in multiple sclerosis, memory Treg frequencies decrease due to their dependence on ongoing costimulation. Clinical translation of these immunological effects varies substantially by disease, with robust benefits observed in GVHD prevention where transient early suppression of donor T-cell activation is sufficient, sustained benefits in established rheumatoid arthritis with high baseline T-cell activation, but no clinical improvement in mild atopic asthma despite similar shifts in T-cell populations. This heterogeneity suggests that costimulation blockade is most effective when CD28-dependent T-cell responses drive disease pathology and baseline immune activation is high.

Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria...

Results

Characteristics of Included Studies

Study Full text retrieved? Disease context Study design Abatacept regimen Primary T-cell measures
J. Kremer et al., 2006 Yes Rheumatoid arthritis with inadequate methotrexate response Randomized, double-blind, placebo-controlled trial ~10 mg/kg IV monthly for 1 year Not specified
M. Weisman et al., 2006 No Active rheumatoid arthritis with inadequate methotrexate response Phase II trial 10 mg/kg or 2 mg/kg for 12 months Inflammatory biomarkers (IL-6, soluble IL-2 receptor)
Divya Koura et al., 2013 Yes Acute GVHD prevention during unrelated-donor HCT First-in-disease trial 10 mg/kg IV on days -1, +5, +14, +28 post-HCT Ki-67 proliferation, CD38/HLA-DR activation, FoxP3+ Tregs
... ... ... ... ... ...

Effects on T-cell Activation

Activation Marker Expression

Abatacept treatment reduced expression of multiple T-cell activation markers across disease contexts. In GVHD prevention, CD4+ T cells showed 7-fold fewer proliferating cells (Ki-67+) and 10-fold fewer activated cells (CD38+/HLA-DR+) at day +28 compared to controls...

Proliferation and Cell Cycle Effects

Transcriptional analysis revealed that abatacept disrupted cell cycle and proliferation pathways in activated T cells...

Inflammatory Biomarkers

Beyond cellular activation markers, abatacept reduced soluble inflammatory mediators associated with T-cell activation...

Effects on T-cell Subset Distribution

Study Context Naive T cells Memory T cells Specialized subsets Effect magnitude
T. Orbán et al., 2014 Type 1 diabetes Increased naive CD4+ T cells Decreased central memory CD4+ T cells Reduced CD4+CD25high Tregs Significant reduction in absolute CM numbers
... ... ... ... ... ...

Effects on Regulatory T Cells and Tolerance

Abatacept’s effects on regulatory T cells varied by subset and assay...

Temporal Dynamics of Effects

Study Context Onset of activation effects Peak effects Reversibility Duration assessed
Divya Koura et al., 2013 GVHD Day +28 Day +28 Yes, effects diminished after treatment cessation Through day +100
... ... ... ... ... ...

Mechanistic Insights into Activation vs. Tolerance

Abatacept’s mechanism extends beyond simple CD80/CD86 blockade to affect multiple cellular processes...

Study Quality and Limitations

Several factors affect interpretation of these findings across studies...

Synthesis

The evidence reveals a consistent pattern: abatacept reduces T-cell activation markers and shifts CD4+ compartments toward naive phenotypes while showing limited effects on CD8+ cells...

References